The increased cardiovascular disease risk in patients with ankylosing spondylitis is explained both by traditional cardiovascular risk factors as well as the underlying chronic inflammatory process. However, this dual etiology is not adequately addressed in clinical practice, according to a presentation on June 3 at the European Congress of Rheumatology (EULAR) annual meeting.
Spondyloarthritis is associated with an increased risk of preterm births, small gestational age infants and elective cesarean section deliveries, according to study data presented on June 4 at the European Congress of Rheumatology (EULAR) annual meeting.
Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.
Rheumatoid arthritis patients with probably major depressive disorder or generalized anxiety disorder were more likely to suffer from worse fatigue and pain.
Dr. Philip Mease explains the relationship between rheumatoid arthritis and psoriatic arthritis.
More patients maintain therapeutic response when treated concomitantly with methotrexate and pegloticase when compared to those who use pegloticase alone.
A team investigated data from trials of tofacitinib, adalimumab, and placebo.
Study drug also recently showed promise in treating psoriatic arthritis.
The safety profile is consistent with previous studies of the ixekizumab.
The safety profile of upadacitinib is consistent with phase 3 rheumatoid arthritis studies.
Remission and LDA rates generally increased over time in patients with psoriatic arthritis receiving tofacitinib.
The late-breaking data reveal the safety and efficacy of upadacitinib versus placebo and adalimumab.
Asian countries regularly see higher rates of SLE prevalence globally.
The incidence rate of serious infection events and opportunistic infections was higher among the upadacitinib 30 mg group than the 15 mg group.
German researchers reported at EULAR this week that patients with rheumatic and musculoskeletal-related pain are increasingly turning to opioids and continue to take them even after the pain subsides.
The findings are based on data from a 24-week observation from an ongoing phase 3 PATERA study.
COVID-19 was center-stage at this year's EULAR meeting. Dr. Pedro Machado, a rheumatologist with the University College London and chair of EULAR's Standing Committee for Epidemiology and Health Service Research shared the results of a study on patients with rheumatic disease who contracted COVID-19. He and his team found that patients taking a higher dose of prednisone, had an increased of being hospitalized. But patients receiving TNF blockers were less likely to be hospitalized. In this interview, Dr. Machado talks with us about the findings.
In a late-breaking abstract, investigators test nanoparticle treatment using in vivo models.
In an abstract presented at EULAR 2020, investigators find more serious adverse events in the upadacitinib treatment arms compared to placebo.
Patients report sustained improvements in pain and fatigue from taking ixekizumab every 2 or 4 weeks over 3 years.
The findings are important to understand treatment persistence and switch patterns in rheumatoid arthritis patients with poor prognostic factors in a real-world setting.
Dr. Gregg Silverman said identification of Ruminococcus gnavus could allow earlier diagnosis of lupus nephritis.
Findings suggest 5-10 mg of tanezumab significantly improve pain versus placebo in patients with chronic low back pain.
Eli Lilly announced this week that Taltz (ixekizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA). And, this week during the EULAR annual meeting, the company is reporting results from the 52-week SPIRIT phase 3b/4 trial for psoriatic arthritis comparing ixekizumab to adalimumab.
The results highlight a significant improvement in rheumatoid arthritis signs and symptoms for those who used upadacitinib over placebo and adalimumab.
Rheumatic disease patients treated with anti-TNF therapy and who contracted COVID-19, were hospitalized less often than patients treated with glucocorticoids, shows an observational study presented on Wednesday at the European Congress of Rheumatology (EULAR) annual meeting-which is being held virtually this week from the homes of more than 18,000 registered attendees.
In a study presented at EULAR, investigators find 14-3-3η baseline levels did not correlate with baseline mTSS.
In both DISCOVER trials, investigators find guselkumab effective against active psoriatic arthritis domains.
The treatment has already proven to reduce oral ulcers associated with Behcet’s syndrome.
Patients are unaffected by the switch from ADL-EU to ADL-PF.
